Global Myocardial Infarction Therapeutics Market Size Study, by Therapeutic Class, by Route of Administration, by Indication, by Mechanism of Action and Regional Forecasts 2024-2032

Description

The Global Myocardial Infarction Therapeutics Market is estimated to be valued at USD 15.56 billion in 2023 and is projected to grow at a CAGR of 4.19% over the forecast period 2024-2032. Myocardial infarction therapeutics encompass a range of treatments aimed at managing and mitigating the effects of a heart attack. These include acute interventions such as thrombolytic therapy, which dissolves blood clots obstructing coronary arteries, and percutaneous coronary interventions (PCI), such as angioplasty and stent placement to restore blood flow. Medications play a crucial role, including antiplatelet agents, anticoagulants, and beta-blockers, which reduce the heart's workload and prevent further clot formation. Long-term management may involve lifestyle modifications, statins to manage cholesterol levels, and medications to control blood pressure. Collectively, these strategies aim to restore heart function, prevent complications, and improve overall prognosis. Furthermore, advances in pharmacology are leading to the development of novel drugs, including new anticoagulants, antiplatelet agents, and drugs targeting specific pathways involved in myocardial infarction. These innovations aim to improve efficacy and reduce side effects.

The substantial growth can be attributed to the increasing prevalence of cardiovascular diseases (CVDs), which have been the leading cause of death globally for the past 15 years. Factors such as sedentary lifestyles, unhealthy diets, tobacco use, and an aging population further contribute to the rising incidence of myocardial infarction, driving the demand for effective therapeutic solutions. Technological advancements in treatment modalities are another significant driver of market growth. Continuous innovation in drug development, including the introduction of novel therapies such as gene therapy, stem cell therapy, and personalized medicine approaches, is expected to enhance treatment outcomes and reduce mortality rates. The adoption of telemedicine and remote patient monitoring also facilitates better access to healthcare services, especially in underserved regions, thus expanding the market reach.

The key region in the Global Myocardial Infarction Therapeutics Market includes North America, Europe, Asia Pacific, Latin America, and Middle East & Africa. In 2023, North America dominates the market in terms of revenue, supported by a well-established healthcare infrastructure, high prevalence of cardiovascular diseases, and robust research and development activities. The region benefits from cutting-edge treatments, including innovative drugs and advanced medical technologies, alongside a strong emphasis on healthcare access and patient management, driving its leading market position. Europe follows closely, driven by an increasing geriatric population and rising healthcare expenditure. The Asia-Pacific region expected to grow at fastest growth rate during the forecast period 2024-2032, due to heightened awareness about cardiovascular health, improving healthcare systems, and rising disposable incomes.

Major market players included in this report are:

Bayer AG
Eli Lilly and Company
Johnson & Johnson
Bristol-Myers Squibb Company
Boehringer Ingelheim International GmbH
Merck & Co., Inc.
Teva Pharmaceutical Industries Ltd.
Abbott Laboratories
Novartis AG
Sanofi Aventis US, LLC
AstraZeneca plc
Pfizer Inc.
Roche Holding AG

The detailed segments and sub-segment of the market are explained below:

By Therapeutic Class:

Antiplatelet Agents
Antithrombotic Agents
Nitrates
Calcium Channel Blockers
Lipid-Lowering Agents

By Route of Administration:

Oral
Intravenous
Subcutaneous
Transdermal

By Indication:

ST-Elevation Myocardial Infarction (STEMI)
Non-ST-Elevation Myocardial Infarction (NSTEMI)
Unstable Angina

By Mechanism of Action:

Platelet Aggregation Inhibitors (P2Y12 Inhibitors, GPIIb/IIIa Inhibitors)
Thrombin Inhibitors
Anticoagulants
Calcium Channel Blockers
HMG-CoA Reductase Inhibitors

By Region:

North America
U.S.
Canada
Europe
UK
Germany
France
Spain
Italy
ROE
Asia Pacific
China
India
Japan
Australia
South Korea
RoAPAC
Latin America
Brazil
Mexico
Rest of Latin America
Middle East & Africa
Saudi Arabia
South Africa
RoMEA

Years considered for the study are as follows:

Historical year - 2022
Base year - 2023
Forecast period - 2024 to 2032

Key Takeaways:

Market Estimates & Forecast for 10 years from 2022 to 2032.
Annualized revenues and regional level analysis for each market segment.
Detailed analysis of geographical landscape with country level analysis of major regions.
Competitive landscape with information on major players in the market.
Analysis of key business strategies and recommendations on future market approach.
Analysis of competitive structure of the market.
Demand side and supply side analysis of the market.

Chapter 1. Global Myocardial Infarction Therapeutics Market Executive Summary

1.1. Global Myocardial Infarction Therapeutics Market Size & Forecast (2022-2032)
1.2. Regional Summary
1.3. Segmental Summary
- 1.3.1. By Therapeutic Class
- 1.3.2. By Route of Administration
- 1.3.3. By Indication
- 1.3.4. By Mechanism of Action
1.4. Key Trends
1.5. Recession Impact
1.6. Analyst Recommendation & Conclusion

Chapter 2. Global Myocardial Infarction Therapeutics Market Definition and Research Assumptions

2.1. Research Objective
2.2. Market Definition
2.3. Research Assumptions
- 2.3.1. Inclusion & Exclusion
- 2.3.2. Limitations
- 2.3.3. Supply Side Analysis
  - 2.3.3.1. Availability
  - 2.3.3.2. Infrastructure
  - 2.3.3.3. Regulatory Environment
  - 2.3.3.4. Market Competition
  - 2.3.3.5. Economic Viability (Consumer's Perspective)
- 2.3.4. Demand Side Analysis
  - 2.3.4.1. Regulatory Frameworks
  - 2.3.4.2. Technological Advancements
  - 2.3.4.3. Environmental Considerations
  - 2.3.4.4. Consumer Awareness & Acceptance
2.4. Estimation Methodology
2.5. Years Considered for the Study
2.6. Currency Conversion Rates

Chapter 3. Global Myocardial Infarction Therapeutics Market Dynamics

3.1. Market Drivers
- 3.1.1. Rising Prevalence of Cardiovascular Diseases
- 3.1.2. Technological Advancements in MI Treatment
- 3.1.3. Increasing Healthcare Expenditure
3.2. Market Challenges
- 3.2.1. High Cost of Treatment
- 3.2.2. Limited Accessibility in Developing Regions
3.3. Market Opportunities
- 3.3.1. Development of Novel Treatments
- 3.3.2. Adoption of Telemedicine and Remote Patient Monitoring
- 3.3.3. Shift Towards Minimally Invasive Procedures

Chapter 4. Global Myocardial Infarction Therapeutics Market Industry Analysis

4.1. Porter's 5 Force Model
- 4.1.1. Bargaining Power of Suppliers
- 4.1.2. Bargaining Power of Buyers
- 4.1.3. Threat of New Entrants
- 4.1.4. Threat of Substitutes
- 4.1.5. Competitive Rivalry
- 4.1.6. Futuristic Approach to Porter's 5 Force Model
- 4.1.7. Porter's 5 Force Impact Analysis
4.2. PESTEL Analysis
- 4.2.1. Political
- 4.2.2. Economical
- 4.2.3. Social
- 4.2.4. Technological
- 4.2.5. Environmental
- 4.2.6. Legal
4.3. Top Investment Opportunity
4.4. Top Winning Strategies
4.5. Disruptive Trends
4.6. Industry Expert Perspective
4.7. Analyst Recommendation & Conclusion

Chapter 5. Global Myocardial Infarction Therapeutics Market Size & Forecasts by Therapeutic Class 2022-2032

5.1. Segment Dashboard
5.2. Global Myocardial Infarction Therapeutics Market: Therapeutic Class Revenue Trend Analysis, 2022 & 2032 (USD Billion)
- 5.2.1. Antiplatelet Agents
- 5.2.2. Antithrombotic Agents
- 5.2.3. Nitrates
- 5.2.4. Calcium Channel Blockers
- 5.2.5. Lipid-Lowering Agents

Chapter 6. Global Myocardial Infarction Therapeutics Market Size & Forecasts by Route of Administration 2022-2032

6.1. Segment Dashboard
6.2. Global Myocardial Infarction Therapeutics Market: Route of Administration Revenue Trend Analysis, 2022 & 2032 (USD Billion)
- 6.2.1. Oral
- 6.2.2. Intravenous
- 6.2.3. Subcutaneous
- 6.2.4. Transdermal

Chapter 7. Global Myocardial Infarction Therapeutics Market Size & Forecasts by Indication 2022-2032

7.1. Segment Dashboard
7.2. Global Myocardial Infarction Therapeutics Market: Indication Revenue Trend Analysis, 2022 & 2032 (USD Billion)
- 7.2.1. ST-Elevation Myocardial Infarction (STEMI)
- 7.2.2. Non-ST-Elevation Myocardial Infarction (NSTEMI)
- 7.2.3. Unstable Angina

Chapter 8. Global Myocardial Infarction Therapeutics Market Size & Forecasts by Mechanism of Action 2022-2032

8.1. Segment Dashboard
8.2. Global Myocardial Infarction Therapeutics Market: Mechanism of Action Revenue Trend Analysis, 2022 & 2032 (USD Billion)
- 8.2.1. Platelet Aggregation Inhibitors (P2Y12 Inhibitors, GPIIb/IIIa Inhibitors)
- 8.2.2. Thrombin Inhibitors
- 8.2.3. Anticoagulants
- 8.2.4. Calcium Channel Blockers
- 8.2.5. HMG-CoA Reductase Inhibitors

Chapter 9. Global Myocardial Infarction Therapeutics Market Size & Forecasts by Region 2022-2032

9.1. North America Myocardial Infarction Therapeutics Market
- 9.1.1. U.S. Myocardial Infarction Therapeutics Market
  - 9.1.1.1. Therapeutic Class Breakdown Size & Forecasts, 2022-2032
  - 9.1.1.2. Route of Administration Breakdown Size & Forecasts, 2022-2032
  - 9.1.1.3. Indication Breakdown Size & Forecasts, 2022-2032
  - 9.1.1.4. Mechanism of Action Breakdown Size & Forecasts, 2022-2032
- 9.1.2. Canada Myocardial Infarction Therapeutics Market
9.2. Europe Myocardial Infarction Therapeutics Market
- 9.2.1. U.K. Myocardial Infarction Therapeutics Market
- 9.2.2. Germany Myocardial Infarction Therapeutics Market
- 9.2.3. France Myocardial Infarction Therapeutics Market
- 9.2.4. Spain Myocardial Infarction Therapeutics Market
- 9.2.5. Italy Myocardial Infarction Therapeutics Market
- 9.2.6. Rest of Europe Myocardial Infarction Therapeutics Market
9.3. Asia-Pacific Myocardial Infarction Therapeutics Market
- 9.3.1. China Myocardial Infarction Therapeutics Market
- 9.3.2. India Myocardial Infarction Therapeutics Market
- 9.3.3. Japan Myocardial Infarction Therapeutics Market
- 9.3.4. Australia Myocardial Infarction Therapeutics Market
- 9.3.5. South Korea Myocardial Infarction Therapeutics Market
- 9.3.6. Rest of Asia Pacific Myocardial Infarction Therapeutics Market
9.4. Latin America Myocardial Infarction Therapeutics Market
- 9.4.1. Brazil Myocardial Infarction Therapeutics Market
- 9.4.2. Mexico Myocardial Infarction Therapeutics Market
- 9.4.3. Rest of Latin America Myocardial Infarction Therapeutics Market
9.5. Middle East & Africa Myocardial Infarction Therapeutics Market
- 9.5.1. Saudi Arabia Myocardial Infarction Therapeutics Market
- 9.5.2. South Africa Myocardial Infarction Therapeutics Market
- 9.5.3. Rest of Middle East & Africa Myocardial Infarction Therapeutics Market

Chapter 10. Competitive Intelligence

10.1. Key Company SWOT Analysis
10.2. Top Market Strategies
10.3. Company Profiles
- 10.3.1. Bristol-Myers Squibb Company
  - 10.3.1.1. Key Information
  - 10.3.1.2. Overview
  - 10.3.1.3. Financial (Subject to Data Availability)
  - 10.3.1.4. Product Summary
  - 10.3.1.5. Market Strategies
- 10.3.2. Boehringer Ingelheim International GmbH
- 10.3.3. Merck & Co., Inc.
- 10.3.4. Teva Pharmaceutical Industries Ltd.
- 10.3.5. Abbott Laboratories
- 10.3.6. Novartis AG
- 10.3.7. Sanofi Aventis US, LLC
- 10.3.8. AstraZeneca plc
- 10.3.9. Pfizer Inc.
- 10.3.10. Roche Holding AG
- 10.3.11. Bayer AG
- 10.3.12. Eli Lilly and Company
- 10.3.13. Johnson & Johnson

Chapter 11. Research Process

11.1. Research Process
- 11.1.1. Data Mining
- 11.1.2. Analysis
- 11.1.3. Market Estimation
- 11.1.4. Validation
- 11.1.5. Publishing
11.2. Research Attributes